"Clinical Study of Inhaled GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)"

Overview

Sponsor-declared trial summary

Key facts

Sponsor

GB002 Inc.

Participant type

Patients

Age range

18-64 years, 65+ years

Gender

Male and Female

Therapeutic area

Diseases [C] - Cardiovascular Diseases [C14]

Trial duration

14 Jul 2021 → ongoing

Decision date (initial)

2024-11-11

Transition trial

Yes

Low-intervention

No

Rare-disease indication

Yes

Vulnerable population

Yes

Funding sources

GB002, Inc.

External identifiers

EU CT number

2024-516754-22-00

EudraCT number

2020-005169-15

ClinicalTrials.gov

NCT04816604

Trial design

CTIS Part I — objectives, methods, condition coding

Main objective

Scope: Efficacy, Safety

"Evaluate the long-term safety and tolerability of orally inhaled seralutinib in subjects with World Health Organization (WHO) Group 1 PH"

Secondary objectives 1

1. "Evaluate the long-term effect of orally inhaled seralutinib on exercise capacity."

Conditions and MedDRA coding

Pulmonary Arterial Hypertension (PAH)

Study design 1 period

Regulatory references

EMA paediatric investigation plan (PIP)

EMEA-002972-PIP02-23

Plan to share IPD

No

Eligibility criteria

Principal inclusion / exclusion criteria as submitted by sponsor

Inclusion criteria 12

1. Adult female subjects aged 18 to 80 years, inclusive, or adult male subjects aged 50 to 80 years, inclusive, at the time of signing the informed consent form (ICF).
2. Subjects must have completed a prior seralutinib PAH study and, in the opinion of the Investigator and Sponsor, have been compliant with study procedures and have completed treatment with IP through parent study EOT visit. See exception(s) for public health emergency visit/procedure delays specified in Appendix 6, Section 10.6.
3. Treatment with standard of care PAH disease-specific background therapies (stable dose).
4. Women of childbearing potential must have a negative urine or serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [hCG]) at extension enrollment visit before first administration of seralutinib in this study. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test is required, and results must be negative.
5. Women of nonchildbearing potential: Evidence of post-menopausal status. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply: Women < 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy tubal ligation [if considered an effective form of sterilization in a specific country or region], or hysterectomy). − Women ≥ 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses > 1 year ago, had chemotherapy-induced menopause with last menses > 1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy, tubal ligation [if considered an effective form of sterilization in a specific country or region], or hysterectomy).
6. Women of childbearing potential who are not abstinent and intend to be sexually active with a non-sterilized male partner must be willing to use a highly effective method of contraception (defined in Appendix 4, Section 10.4) from consent through 30 days following the last administration of seralutinib; acceptable methods include hormonal contraception (oral contraceptives – as long as on stable dose, patch, implant, or injection), intrauterine devices or other form of highly effective contraception.
7. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject. Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable.
8. Nota: la abstinencia sexual solamente es aceptable si está en consonancia con el estilo de vida preferido y habitual de la paciente. La abstinencia periódica, el método del ritmo y el coitus interruptus (marcha atrás) no se consideran aceptables.
9. Male subjects: Non-sterilized male subjects who are not abstinent and intend to be sexually active with a female partner of childbearing potential must use a male condom from consent through 90 days after the last dose of seralutinib. Male subjects should refrain from sperm donation throughout this period (except for male subjects participating in fertility analysis as part of this protocol).
10. . Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject. Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable.
11. Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study prior to initiation of any protocol-mandated procedures.
12. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion criteria 21

1. Medical Conditions: 1. Persistent and clinically significant systemic hypertension as evidenced by sitting systolic blood pressure > 160 mm Hg or sitting diastolic blood pressure > 100 mm Hg after a period of rest at the extension study initial visit, or hypotension as evidenced by systolic blood pressure < 90 mm Hg during the extension study initial visit. 2. Interval history of newly developed left-sided heart disease with onset or severity increased after participation in the parent study, and/or clinically significant cardiac disease, including but not limited to any of the following: a. Aortic or mitral valve disease (stenosis or regurgitation) defined as greater than mild aortic insufficiency, mild aortic stenosis (AS), mild mitral stenosis (MS), moderate mitral regurgitation (MR); b. Mechanical or bioprosthetic cardiac valve; c. Pericardial constriction or pericardial effusion with tamponade physiology; d. Restrictive or congestive cardiomyopathy; e. Left ventricular ejection fraction (LVEF) ≤50%. f. Symptomatic coronary disease; g. Significant (2+ for regurgitation) valvular disease other than tricuspid or pulmonary regurgitation; h. Acutely decompensated left heart failure within 1 month (30 days) of extension enrollment visit; i. History of severe and untreated obstructive sleep apnea. 3. Potentially life-threatening cardiac arrhythmia with an ongoing risk. 4. Uncontrolled bacterial, viral, or fungal infections which require systemic therapy. 5. Other severe acute or chronic medical or laboratory abnormality that may increase the risk associated with study participation or seralutinib administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the subject inappropriate for entry into this study; including but not necessarily limited to the following: malignancy within 5 years of extension enrollment visit, with the exception of effectively treated or excised localized non-metastatic basal cell carcinoma of the skin and in situ carcinoma of the cervix; psychiatric disorder that compromises ability to give informed consent, substance abuse, coagulopathy, history of stroke, transient ischemic attack (TIA) requiring concurrent oral coagulation therapy, or intracranial hemorrhage; history of pulmonary embolus or deep vein thrombosis (DVT), history of vasovagal syncope with phlebotomy. 6. Currently pregnant or breastfeeding or intends to become pregnant during the duration of the study. 7. History of portopulmonary hypertension or portal hypertension due to cirrhosis classified as Child-Pugh Class A or higher.
2. Interval history of newly developed left-sided heart disease with onset or severity increased after participation in the parent study, and/or clinically significant cardiac disease, including but not limited to any of the following: a. Aortic or mitral valve disease (stenosis or regurgitation) defined as greater than mild aortic insufficiency, mild aortic stenosis (AS), mild mitral stenosis (MS), moderate mitral regurgitation (MR); b. Mechanical or bioprosthetic cardiac valve; c. Pericardial constriction or pericardial effusion with tamponade physiology; d. Restrictive or congestive cardiomyopathy; e. Left ventricular ejection fraction (LVEF) ≤50%. f. Symptomatic coronary disease; g. Significant (2+ for regurgitation) valvular disease other than tricuspid or pulmonary regurgitation; h. Acutely decompensated left heart failure within 1 month (30 days) of extension enrollment visit; i. History of severe and untreated obstructive sleep apnea.
3. Potentially life-threatening cardiac arrhythmia with an ongoing risk.
4. Uncontrolled bacterial, viral, or fungal infections which require systemic therapy.
5. Other severe acute or chronic medical or laboratory abnormality that may increase the risk associated with study participation or seralutinib administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the subject inappropriate for entry into this study; including but not necessarily limited to the following: malignancy within 5 years of extension enrollment visit, with the exception of effectively treated or excised localized non-metastatic basal cell carcinoma of the skin and in situ carcinoma of the cervix; psychiatric disorder that compromises ability to give informed consent, substance abuse, coagulopathy, history of stroke, transient ischemic attack (TIA) requiring concurrent oral coagulation therapy, or intracranial hemorrhage; history of pulmonary embolus or deep vein thrombosis (DVT), history of vasovagal syncope with phlebotomy.
6. Currently pregnant or breastfeeding or intends to become pregnant during the duration of the study.
7. History of portopulmonary hypertension or portal hypertension due to cirrhosis classified as Child-Pugh Class A or higher.
8. Subjects with a history of severe milk protein allergy. In addition, subjects with known intolerance or hypersensitivity to lactose who, in the opinion of the Investigator, may experience severe symptoms following the ingestion of lactose.
9. Sujetos con antecedentes de alergia severa a proteínas de la leche. Asimismo, sujetos con intolerancia o hipersensibilidad conocida a la lactosa que, en opinión del investigador, puedan experimentar síntomas intensos tras la ingestión de lactosa.
10. Current alcohol use disorder as defined by DSM-5, and/or history of current utilization of drugs of abuse (amphetamines, methamphetamines, cocaine, phencyclidine [PCP]).
11. Have any other condition or reason that, in the opinion of the Investigator and/or the Sponsor’s Medical Monitor (or designee), would prohibit the subject from participating in the study. Diagnostic Assessments The most recent laboratory assessment from the parent study may be used to evaluate laboratory-associated exclusion criterion, if performed within 6 weeks (± 2 days) of the extension enrollment visit.
12. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2 × upper limit of normal (ULN) or total bilirubin ≥ 2 × ULN.
13. Chronic renal insufficiency as defined by an estimated glomerular filtration rate (eGFR) < 45 mL/min/1.73m2 via CKD-EPI (Levey, 2009) at extension study initial visit or requires dialytic therapy or hemofiltration.
14. Hemoglobin (Hgb) concentration < 8.5 g/dL.
15. Absolute neutrophil count (ANC) < 1 x 109/L.
16. Platelet count < 50 x 109/L.
17. Body weight ≤ 40 kg at extension study initial visit.
18. Body weight ≤ 40 kg at extension study initial visit. Prior Therapy
19. Use of inhaled prostanoids.
20. Chronic use of oral anticoagulants (ie, vitamin K antagonist such as warfarin or novel oral anticoagulant [NOAC]/direct oral anticoagulant [DOAC]); if on warfarin or a NOAC it is clinically acceptable to be withdrawn 1 month prior to start of GB002 (see Appendix 5, Section 10.5 for examples of prohibited anticoagulants).
21. Uso crónico de anticoagulantes orales (es decir, antagonistas de la vitamina K, como warfarina o anticoagulantes orales nuevos [NOAC]/anticoagulantes orales de acción directa [DOAC]); si se está recibiendo warfarina o algún NOAC, es aceptable desde el punto de vista clínico retirarlo 1 mes antes de comenzar la administración de GB002 (véase el apéndice 5, sección 10.5 para obtener ejemplos de anticoagulantes prohibidos).

Endpoints

Primary and secondary outcome measures (English text)

Primary endpoints 1

1. Incidence of treatment-emergent adverse events (TEAEs)

Secondary endpoints 1

1. Change in the distance achieved on six-minute walk test (6MWT), (Δ6MWD)

Investigational products

Investigational medicinal products (IMPs), comparators, placebo, auxiliary

Test 1

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

GB002 Inc.

Sponsor organisation

GB002 Inc.

Address

3115 Merryfield Row Suite 120

City

San Diego

Postcode

92121-1174

Country

United States

Scientific contact point

Organisation

GB002 Inc.

Contact name

Clinical Trials Information Website

Public contact point

Organisation

GB002 Inc.

Contact name

Clinical Trials Information Website

Third parties 17

Locations

3 EU/EEA countries · 8 investigational sites

By country

Investigational sites

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Results and documents

Annex IV summary of results, Annex V layperson summary, and all documents registered in CTIS for this trial

Documents 47 files

Public protocol annexes, IB summaries, regulatory submissions and post-authorisation documents registered in CTIS.

Application history

4 submissions — initial application plus substantial / non-substantial modifications